Skip to main content

Advertisement

Log in

A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures

  • Review
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

This review was aimed at the evolution of health economic models used in evaluations of clinical approaches aimed at preventing osteoporotic fractures. Models have improved, with medical continuance becoming increasingly recognized as a contributor to health and economic outcomes, as well as advancements in epidemiological data. Model-based health economic evaluation studies are increasingly used to investigate the cost-effectiveness of osteoporotic fracture preventions and treatments. The objective of this study was to carry out a systematic review of the evolution of health economic models used in the evaluation of osteoporotic fracture preventions. Electronic searches within MEDLINE and EMBASE were carried out using a predefined search strategy. Inclusion and exclusion criteria were used to select relevant studies. References listed of included studies were searched to identify any potential study that was not captured in our electronic search. Data on country, interventions, type of fracture prevention, evaluation perspective, type of model, time horizon, fracture sites, expressed costs, types of costs included, and effectiveness measurement were extracted. Seventy-four models were described in 104 publications, of which 69 % were European. Earlier models focused mainly on hip, vertebral, and wrist fracture, but later models included multiple fracture sites (humerus, pelvis, tibia, and other fractures). Modeling techniques have evolved from simple decision trees, through deterministic Markov processes to individual patient simulation models accounting for uncertainty in multiple parameters. Treatment continuance has been increasingly taken into account in the models in the last decade. Models have evolved in their complexity and emphasis, with medical continuance becoming increasingly recognized as a contributor to health and economic outcomes. This evolution may be driven in part by the desire to capture all the important differentiating characteristics of medications under scrutiny, as well as the advancement in epidemiological data relevant to osteoporosis fractures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Glaser DL, Kaplan FS (1997) Osteoporosis: definition and clinical presentation. Spine 22:12S–16S

    Article  CAS  PubMed  Google Scholar 

  2. Economics A, Australia O (2001) The burden of brittle bones: costing osteoporosis in Australia. Access Economics, Canberra

  3. Welfare AIoHa (2011) A snapshot of osteoporosis in Australia 2011. Australian Institute of Health and Welfare, Canberra.

  4. Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767

    Article  PubMed  Google Scholar 

  5. Dimai HP, Redlich K, Peretz M, Borgström F, Siebert U, Mahlich J (2012) Economic burden of osteoporotic fractures in Austria. Heal Econ Rev 2:1–10

    Article  Google Scholar 

  6. Schwenkglenks M, Lippuner K, Hauselmann HJ, Szucs TD (2005) A model of osteoporosis impact in Switzerland 2000–2020. Osteoporos Int 16:659–671

    Article  PubMed  Google Scholar 

  7. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513–521

    Article  CAS  PubMed  Google Scholar 

  8. Johnell O, Kanis J, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38–42

    Article  CAS  PubMed  Google Scholar 

  9. Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152:380–380

    Article  PubMed Central  PubMed  Google Scholar 

  10. Kanis JA, Johnell O, Oden A et al (2004) The risk and burden of vertebral fractures in Sweden. Osteoporosis international 15:20–26

    Article  CAS  PubMed  Google Scholar 

  11. Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd Jones M (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 6:1–146

    CAS  PubMed  Google Scholar 

  12. Stevenson M, Davis S, Lloyd-Jones M, Beverley C (2007) The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. Health Technol Assess 11:1–134

    CAS  PubMed  Google Scholar 

  13. Hiligsmann M, Bruyere O, Reginster JY (2010) Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporos Int 21:157–165

    Article  CAS  PubMed  Google Scholar 

  14. Weinstein MC, Toy EL, Sandberg EA, Neumann PJ, Evans JS, Kuntz KM, Graham JD, Hammitt JK (2001) Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 4:348–361

    Article  CAS  PubMed  Google Scholar 

  15. Briggs A, Sculpher M, Claxton K (2006) Decision modelling for health economic evaluation. Oxford University Press, New York

    Google Scholar 

  16. Hersh AL, Black WC, Tosteson AN (1999) Estimating the population impact of an intervention: a decision-analytic approach. Stat Methods Med Res 8:311–330

    Article  CAS  PubMed  Google Scholar 

  17. Zethraeus N, Ben Sedrine W, Caulin F et al (2002) Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int 13:841–857

    Article  CAS  PubMed  Google Scholar 

  18. Zethraeus N, Borgstrom F, Strom O, Kanis JA, Jonsson B (2007) Cost-effectiveness of the treatment and prevention of osteoporosis—a review of the literature and a reference model. Osteoporos Int 18:9–23

    Article  CAS  PubMed  Google Scholar 

  19. Papapoulos S, Chapurlat R, Libanati C et al (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 27:694–701

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097

    Article  PubMed Central  PubMed  Google Scholar 

  21. Group CaCEM, Centre EfPaPIaC (2013) CCEMG–EPPI-Centre Cost Converter. http://eppi.ioe.ac.uk/costconversion/default.aspx. Accessed 24 Apr 2013

  22. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44–47

    Article  PubMed  Google Scholar 

  23. Jonsson B, Kanis J, Dawson A, Oden A, Johnell O (1999) Effect and offset of effect of treatments for hip fracture on health outcomes. Osteoporos Int 10:193–199

    Article  CAS  PubMed  Google Scholar 

  24. Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (Fosamax (registered trademark)) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305–314

    Article  PubMed  Google Scholar 

  25. Borgstrom F, Carlsson A, Sintonen H, Boonen S, Haentjens P, Burge R, Johnell O, Jonsson B, Kanis JA (2006) The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int 17:996–1007

    Article  CAS  PubMed  Google Scholar 

  26. Strom O, Borgstrom F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries—an economic evaluation based on the fracture intervention trial. Osteoporos Int 18:1047–1061

    Article  CAS  PubMed  Google Scholar 

  27. Tosteson ANA, Jönsson B, Grima DT, O’Brien BJ, Black DM, Adachi JD (2001) Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 12:849–857

    Article  CAS  PubMed  Google Scholar 

  28. Thompson M, Pasquale M, Grima D, Moehrke W, Kruse HP (2010) The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis. Value Health 13:46–54

    Article  PubMed  Google Scholar 

  29. Alzahouri K, Bahrami S, Durand-Zaleski I, Guillemin F, Roux C (2013) Cost-effectiveness of osteoporosis treatments in postmenopausal women using FRAX (trademark) thresholds for decision. Joint Bone Spine 80:64–69

    Article  PubMed  Google Scholar 

  30. Fleurence RL (2004) Cost-effectiveness of fracture prevention treatments in the elderly. Int J Technol Assess Health Care 20:184–191

    Article  PubMed  Google Scholar 

  31. Tosteson ANA, Burge RT, Marshall DA, Lindsay R (2008) Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manage Care 14:605–615

    Google Scholar 

  32. Strom O, Borgstrom F, Kleman M, McCloskey E, Oden A, Johansson H, Kanis JA (2010) FRAX and its applications in health economics–cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone 47:430–437

    Article  CAS  PubMed  Google Scholar 

  33. Stevenson MD, Brazier JE, Calvert NW, Lloyd-Jones M, Oakley JE, Kanis JA (2005) Description of an individual patient methodology for calculating the cost-effectiveness of treatments for osteoporosis in women. J Oper Res Soc 56:214–221

    Article  Google Scholar 

  34. Nayak S, Roberts MS, Greenspan SL (2011) Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med 155:751–761

    Article  PubMed Central  PubMed  Google Scholar 

  35. Tosteson AN, Gabriel SE, Grove MR, Moncur MM, Kneeland TS, Melton LJ 3rd (2001) Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 12:1042–1049

    Article  CAS  PubMed  Google Scholar 

  36. Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D, Jonsson B (2005) Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 16:15–25

    Article  CAS  PubMed  Google Scholar 

  37. Earnshaw SR, Graham CN, Ettinger B, Amonkar MM, Lynch NO, Middelhoven H (2007) Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Curr Med Res Opin 23:2517–2529

    Article  CAS  PubMed  Google Scholar 

  38. Hiligsmann M, Ethgen O, Bruyere O, Reginster JY (2008) An economic evaluation of quantitative ultrasonometry as pre-screening test for the identification of patients with osteoporosis. Disease Management and Health Outcomes 16:429–438

    Article  Google Scholar 

  39. Wasserfallen JB, Krieg MA, Greiner RA, Lamy O (2008) Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective. J Med Econ 11:499–523

    Article  PubMed  Google Scholar 

  40. Hiligsmann M, Ethgen O, Bruyere O, Richy F, Gathon HJ, Reginster JY (2009) Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 12:687–696

    Article  PubMed  Google Scholar 

  41. Hiligsmann M, Reginster JY (2010) Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone 47:34–40

    Article  CAS  PubMed  Google Scholar 

  42. Murphy DR, Smolen LJ, Klein TM, Klein RW (2012) The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden. BMC musculoskelet Disord 13:213–213

    Article  PubMed Central  PubMed  Google Scholar 

  43. Hiligsmann M, Bruyere O, Reginster JY (2010) Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. Bone 46:440–446

    Article  CAS  PubMed  Google Scholar 

  44. Hiligsmann M, Reginster JY (2011) Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics 29:895–911

    Article  PubMed  Google Scholar 

  45. Hiligsmann M, McGowan B, Bennett K, Barry M, Reginster JY (2012) The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health 15:604–612

    Article  PubMed  Google Scholar 

  46. Ding H, Koinuma N, Stevenson M, Ito M, Monma Y (2008) The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis. J Bone Miner Metab 26:34–41

    Article  CAS  PubMed  Google Scholar 

  47. Kanis JA, Borgstrom F, Johnell O, Jonsson B (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 15:862–871

    Article  CAS  PubMed  Google Scholar 

  48. Borgstrom F, Johnell O, Kanis JA et al (2006) At what hip fracture risk is it cost-effective to treat?: international intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17:1459–1471

    Article  CAS  PubMed  Google Scholar 

  49. Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21:495–505

    Article  CAS  PubMed  Google Scholar 

  50. Akehurst R, Brereton N, Ariely R, Lusa T, Groot M, Foss P, Boonen S (2011) The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands. J Med Econ 14:53–64

    Article  CAS  PubMed  Google Scholar 

  51. Borgstrom F, Strom O, Kleman M, McCloskey E, Johansson H, Oden A, Kanis JA (2011) Cost-effectiveness of bazedoxifene incorporating the FRAX(R) algorithm in a European perspective. Osteoporos Int 22:955–965

    Article  CAS  PubMed  Google Scholar 

  52. Kanis JA, Adams J, Borgstrom F, Cooper C, Jonsson B, Preedy D, Selby P, Compston J (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42:4–15

    Article  CAS  PubMed  Google Scholar 

  53. Daly E, Roche M, Barlow D, Gray A, McPherson K, Vessey M (1992) HRT: an analysis of benefits, risks and costs. Br Med Bull 48:368–400

    CAS  PubMed  Google Scholar 

  54. Hiligsmann M, Gathon HJ, Bruyere O, Ethgen O, Rabenda V, Reginster JY (2010) Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health 13:394–401

    Article  PubMed  Google Scholar 

  55. Cundy T, Cornish J, Evans MC, Gamble G, Stapleton J, Reid IR (1995) Sources of interracial variation in bone-mineral density. J Bone Miner Res 10:368–373

    Article  CAS  PubMed  Google Scholar 

  56. Ross PD, He YF, Yates AJ, Coupland C, Ravn P, McClung M, Thompson D, Wasnich RD (1996) Body size accounts for most differences in bone density between Asian and Caucasian women. Calcif Tissue Int 59:339–343

    Article  CAS  PubMed  Google Scholar 

  57. Jonsson B, Strom O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, Kanis JA (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22:967–982

    Article  CAS  PubMed  Google Scholar 

  58. Sculpher M, Fenwick E, Claxton K (2000) Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application. Pharmacoeconomics, 17(5):461-477

  59. Soto J (2002) Health economic evaluations using decision analytic modeling. Principles and practices—utilization of a checklist to their development and appraisal. Int J Technol Assess Health Care 18:94–111

    PubMed  Google Scholar 

  60. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR (2003) Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices—modeling studies. Value Health 6:9–17

    Article  PubMed  Google Scholar 

  61. Sonnenberg FA, Beck JR (1993) Markov-models in medical decision-making: a practical guide. Med Decis Mak 13:322–338

    Article  CAS  Google Scholar 

  62. Palmer AJ, Stephane R, Valentine WJ, Minshall ME et al (2004) Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 20:S27–S40

    Article  PubMed  Google Scholar 

  63. Briggs A, Sculpher M (1998) An introduction to Markov modelling for economic evaluation. PharmacoEconomics 13:397–397

    Article  CAS  PubMed  Google Scholar 

  64. van Staa TP, Kanis JA, Geusens P, Boonen A, Leufkens HG, Cooper C (2007) The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks. Value Health 10:348–357

    Article  PubMed  Google Scholar 

  65. Schousboe JT, Ensrud KE, Nyman JA, Melton LJ 3rd, Kane RL (2005) Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J Am Geriatr Soc 53:1697–1704

    Article  PubMed  Google Scholar 

  66. Cotte FE, De Pouvourville G (2011) Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France. BMC Health Serv Res 11:151

    Article  PubMed Central  PubMed  Google Scholar 

  67. Akehurst R, Dixon S, Fryback D et al (2000) Decision analytic modelling in the economic evaluation of health technologies: a consensus statement. PharmacoEconomics 17:443–443

    Article  Google Scholar 

  68. Gold M, Siegel J, Russell L, Weistein M (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York

    Google Scholar 

  69. Hay J, Jackson J, Luce B, Avorn J, Ashraf T (1999) Panel 2: methodological issues in conducting pharmacoeconomic evaluations—modeling studies. Value Health 2:78–81

    Article  CAS  PubMed  Google Scholar 

  70. Cleemput I, van Wilder P, Huybrechts M, Vrijens F (2009) Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. Value Health 12:441–449

    Article  PubMed  Google Scholar 

  71. Gandjour A, Weyler EJ (2008) Cost-effectiveness of preventing hip fractures by hip protectors in elderly institutionalized residents in Germany. Value Health 11:1088–1095

    Article  PubMed  Google Scholar 

  72. Pike C, Birnbaum HG, Schiller M, Sharma H, Burge R, Edgell ET (2010) Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US. PharmacoEconomics 28:395–395

    Article  PubMed  Google Scholar 

  73. Nuijten MJ, Pronk MH, Brorens MJ, Hekster YA, Lockefeer JH, de Smet PA, Bonsel G, van der Kuy A (1998) Reporting format for economic evaluation. Part II: focus on modelling studies. PharmacoEconomics 14:259–259

    Article  CAS  PubMed  Google Scholar 

  74. Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T, Vray M (1997) Modelling in economic evaluation: an unavoidable fact of life. Health Econ 6:217–227

    Article  CAS  PubMed  Google Scholar 

  75. Sonnenberg FA, Roberts MS, Tsevat J, Wong JB, Barry M, Kent DL (1994) Toward a peer review process for medical decision analysis models. Med Care 32:JS52–JS64

    Article  CAS  PubMed  Google Scholar 

  76. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739

    Article  CAS  PubMed  Google Scholar 

  77. Johnell O, Kanis JA, Odén A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jönsson B (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15:175–179

    Article  CAS  PubMed  Google Scholar 

  78. Lundkvist J, Johnell O, Cooper C, Sykes D (2006) Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women. Osteoporos Int 17:201–211

    Article  CAS  PubMed  Google Scholar 

  79. Borgstrom F, Strom O, Marin F, Kutahov A, Ljunggren O (2010) Cost effectiveness of teriparatide and PTH(1–84) in the treatment of postmenopausal osteoporosis. J Med Econ 13:381–392

    Article  PubMed  Google Scholar 

  80. Weinstein MC (1980) Estrogen use in postmenopausal women—costs, risks, and benefits. N Engl J Med 303:308–316

    Article  CAS  PubMed  Google Scholar 

  81. Tosteson AN, Rosenthal DI, Melton LJ 3rd, Weinstein MC (1990) Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 113:594–603

    Article  CAS  PubMed  Google Scholar 

  82. Weinstein MC, Tosteson ANA (1990) Cost-effectiveness of hormone replacement. Ann N Y Acad Sci 592:162–172

    Article  CAS  PubMed  Google Scholar 

  83. Tosteson ANA, Weinstein MC (1991) Cost-effectiveness of hormone replacement therapy after the menopause. Baillieres Clin Obstet Gynaecol 5:943–959

    Article  CAS  PubMed  Google Scholar 

  84. Cheung AP, Wren BG (1992) A cost-effectiveness analysis of hormone replacement therapy in the menopause. Med J Aust 156:312–316

    CAS  PubMed  Google Scholar 

  85. Zethraeus N, Borgstrom F, Jonsson B, Kanis J (2005) Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the women's health initiative randomized controlled trial. Int J Technol Assess Health Care 21:433–441

    Article  PubMed  Google Scholar 

  86. Mobley LR, Hoerger TJ, Wittenborn JS, Galuska DA, Rao JK (2006) Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Med Decis Mak 26:194–206

    Article  Google Scholar 

  87. Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321–333

    Article  CAS  PubMed  Google Scholar 

  88. Neer RM, Genant HK, Wang O et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441

    Article  CAS  PubMed  Google Scholar 

  89. Deil IJ, Bergner R, Grotz KA (2007) Adverse effects of bisphosphonates: current issues. J Support Oncol, 5:475-482

    Google Scholar 

  90. Woo S-B, Hellstein JW, Kalmar JR (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761

    Article  CAS  PubMed  Google Scholar 

  91. Need AG, Horowitz M, Walker CJ, Chatterton BE, Chapman IC, Nordin BE (1989) Cross-over study of fat-corrected forearm mineral content during nandrolone decanoate therapy for osteoporosis. Bone 10:3–6

    Article  CAS  PubMed  Google Scholar 

  92. Ettinger B, Pressman A, Schein J (1998) Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manage Care 4:1377–1382

    CAS  Google Scholar 

  93. Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA (1998) Lifetime risk of hip fractures is underestimated. Osteoporos Int 8:599–603

    Article  CAS  PubMed  Google Scholar 

  94. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468–473

    Article  CAS  PubMed  Google Scholar 

  95. Hiligsmann M, Rabenda V, Bruyere O, Reginster JY (2010) The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 96:170–177

    Article  PubMed  Google Scholar 

  96. Singh S, Sun H, Anis AH (2004) Cost-effectiveness of hip protectors in the prevention of osteoporosis related hip fractures in elderly nursing home residents. J Rheumatol 31:1607–1613

    PubMed  Google Scholar 

  97. Drummond MF, Jefferson TO (1996) Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 313:275–283

    Article  CAS  PubMed  Google Scholar 

  98. Husereau D, Loder E, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J (2013) Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Eur J Health Econ 14:367–372

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to L. Si.

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

ESM 1

(PDF 87 kb)

ESM 2

(PDF 119 kb)

ESM 3

(PDF 203 kb)

ESM 4

(PDF 209 kb)

ESM 5

(PDF 147 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Si, L., Winzenberg, T.M. & Palmer, A.J. A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures. Osteoporos Int 25, 51–60 (2014). https://doi.org/10.1007/s00198-013-2551-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-013-2551-y

Keywords

Navigation